# US 2024/0189495 A1 · Methods of preparing an extracorporeal circuit for anticoagulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189495 A1
- Document ID: US20240189495A1
- Status: Published application
- Kind: A1
- Application number: 18/287,784
- Filed: 2022-04-08
- Published: 2024-06-13
- Earliest claimed: 2021-04-20
- Assignees: Lawell Therapeutics, LLC
- Applicants: Lawell Therapeutics, LLC
- Inventors: James A. Wilkie; Lakhmir Chawla
- Web page: https://patentgrep.com/patent/US20240189495A1

## CPC

- A61M 1/3672: {Means preventing coagulation}
- A61M 1/3643: {Priming, rinsing before or after use}
- A61M 1/3644: {Mode of operation}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present disclosure provides methods of preparing an extracorporeal circuit for circulating blood. The methods of preparation include ascertaining the adsorptive potential of an anticoagulant to a filter membrane material and adjusting priming of the circuit in accordance.

## Claims

### Claim 1

A method of preparing an extracorporeal circuit for blood flow through the circuit, the method comprising
ascertaining the adsorptive potential of an anticoagulant to a filter membrane material within the extracorporeal circuit;
determining a priming quantity of the anticoagulant for the extracorporeal circuit based on the adsorptive potential;
determining a duration of system priming; and
infusing the priming quantity of the anticoagulant into the extracorporeal circuit for the selected duration of system priming.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anticoagulant is also a protease inhibitor or a thrombin inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the adsorptive potential is ascertained to be low.

### Claim 4 (depends on 3)

The method of claim 3, wherein the filter membrane material comprises polysulfone (PS), polyethersulfone (PES), or polyarylethersulfone (PAES).

### Claim 5 (depends on 3)

The method of claim 3, wherein the priming quantity is 2 mg to 5 mg.

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein said duration of system priming is 5 mins to 30 mins.

### Claim 8

(canceled)

### Claim 9 (depends on 3)

The method of claim 3, further comprising initiating blood flow in the extracorporeal circuit before the expiration of the priming effect; no later than 2, 3, 4, 5, 6, 7, 8, 9, or 10 mins after said duration of system priming; or after initiating a post-priming infusion of the anticoagulant into the extracorporeal circuit.

### Claim at position 10

10-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the adsorptive potential is ascertained to be high.

### Claim 14 (depends on 13)

The method of claim 13, wherein the filter membrane material comprises polyacrylonitrile (PAN).

### Claim 15 (depends on 13)

The method of claim 13, wherein the priming quantity is 2 mg to 40 mg.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein said duration is 2 mins to 5 mins.

### Claim 18

(canceled)

### Claim 19 (depends on 13)

The method of claim 13, further comprising initiating blood flow in the extracorporeal circuit before the expiration of the priming effect; no later than 2, 3, 4, or 5 mins after said duration of priming; or after initiating a post-priming infusion of the anticoagulant into the extracorporeal circuit.

### Claim at position 18

20-22. (canceled)

### Claim 23

A method of preparing an extracorporeal circuit for blood flow through the circuit, the method comprising
ascertaining the adsorptive potential of an anticoagulant to a filter membrane material within the extracorporeal circuit;
determining a duration of system priming; and
infusing a priming solution into the extracorporeal circuit for the selected duration of system priming.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anticoagulant is also a protease inhibitor or a thrombin inhibitor.

### Claim 25 (depends on 23)

The method of claim 23, wherein the priming solution comprises anticoagulant-free saline and/or a priming quantity of the anticoagulant.

### Claim 26 (depends on 23)

The method of claim 23, wherein the adsorptive potential is ascertained to be high.

### Claim 27 (depends on 26)

The method of claim 26, wherein the filter membrane material comprises polyacrylonitrile (PAN).

### Claim 28 (depends on 26)

The method of claim 26, wherein said duration is 2 mins to 5 mins.

### Claim 29

(canceled)

### Claim 30 (depends on 26)

The method of claim 26, further comprising initiating blood flow in the extracorporeal circuit, wherein blood flow is initiated not later than 5 mins after said duration of system priming.

### Claim at position 27

31-32. (canceled)

### Claim 33 (depends on 26)

The method of claim 26, further comprising initiating blood flow in the extracorporeal circuit after initiating post-priming infusion of said anticoagulant into the extracorporeal circuit.

### Claim 34 (depends on 1)

The method of claim 1, further comprising adjusting the prime quantity of the anticoagulant based on filter membrane surface area, wherein said adjusting is linearly proportional.

### Claim at position 30

35-37. (canceled)

### Claim 38 (depends on 2)

The method of claim 2, wherein the anticoagulant is also a protease inhibitor or a thrombin inhibitor selected from nafamostat, nafamostat mesylate, or another salt form of nafamostat, abexate, gabexate mesylate, or another salt form of gabexate, hirudin, bivalirudin, desirudin, lepirudin, argatroban, dabigatran, efegatran, inogatran, melagatran, nafamostat, ximelagatran, gabexate, camostat, or another salt form thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the anticoagulant is nafamostat mesylate and the priming quantity is with respect to nafamostat free-base.

### Claim at position 33

40-42. (canceled)

### Claim 43 (depends on 24)

The method of claim 24, wherein the anticoagulant is also a protease inhibitor or a thrombin inhibitor selected from nafamostat, nafamostat mesylate, or another salt form of nafamostat, abexate, gabexate mesylate, or another salt form of gabexate, hirudin, bivalirudin, desirudin, lepirudin, argatroban, dabigatran, efegatran, inogatran, melagatran, nafamostat, ximelagatran, gabexate, camostat, or another salt form thereof.

### Claim 44 (depends on 43)

The method of claim 43, wherein the anticoagulant is nafamostat mesylate and the priming quantity is with respect to nafamostat free-base.
